Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

Age-related variations in gene expression patterns of renal cell carcinoma.

Feulner L, Najafabadi HS, Tanguay S, Rak J, Riazalhosseini Y.

Urol Oncol. 2019 Feb;37(2):166-175. doi: 10.1016/j.urolonc.2018.11.006. Epub 2018 Nov 23.

PMID:
30478010
2.

Aberration hubs in protein interaction networks highlight actionable targets in cancer.

Karimzadeh M, Jandaghi P, Papadakis AI, Trainor S, Rung J, Gonzàlez-Porta M, Scelo G, Vasudev NS, Brazma A, Huang S, Banks RE, Lathrop M, Najafabadi HS, Riazalhosseini Y.

Oncotarget. 2018 May 18;9(38):25166-25180. doi: 10.18632/oncotarget.25382. eCollection 2018 May 18.

3.

A General Framework for Interrogation of mRNA Stability Programs Identifies RNA-Binding Proteins that Govern Cancer Transcriptomes.

Perron G, Jandaghi P, Solanki S, Safisamghabadi M, Storoz C, Karimzadeh M, Papadakis AI, Arseneault M, Scelo G, Banks RE, Tost J, Lathrop M, Tanguay S, Brazma A, Huang S, Brimo F, Najafabadi HS, Riazalhosseini Y.

Cell Rep. 2018 May 8;23(6):1639-1650. doi: 10.1016/j.celrep.2018.04.031.

4.

Consequences of VHL Loss on Global DNA Methylome.

Robinson CM, Lefebvre F, Poon BP, Bousard A, Fan X, Lathrop M, Tost J, Kim WY, Riazalhosseini Y, Ohh M.

Sci Rep. 2018 Feb 20;8(1):3313. doi: 10.1038/s41598-018-21524-5.

5.

Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer.

Mishra RR, Belder N, Ansari SA, Kayhan M, Bal H, Raza U, Ersan PG, Tokat ÜM, Eyüpoğlu E, Saatci Ö, Jandaghi P, Wiemann S, Üner A, Cekic C, Riazalhosseini Y, Şahin Ö.

Clin Cancer Res. 2018 Apr 15;24(8):1987-2001. doi: 10.1158/1078-0432.CCR-17-2776. Epub 2018 Jan 31.

PMID:
29386221
6.

The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples.

Wever CM, Geoffrion D, Grande BM, Yu S, Alcaide M, Lemaire M, Riazalhosseini Y, Hébert J, Gavino C, Vinh DC, Petrogiannis-Haliotis T, Dmitrienko S, Mann KK, Morin RD, Johnson NA.

Leuk Lymphoma. 2018 Sep;59(9):2159-2174. doi: 10.1080/10428194.2017.1413186. Epub 2018 Jan 3.

PMID:
29295643
7.

Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma.

Mehdi A, Riazalhosseini Y.

Int J Mol Sci. 2017 Aug 16;18(8). pii: E1774. doi: 10.3390/ijms18081774. Review.

8.

Loss of chromosome Y leads to down regulation of KDM5D and KDM6C epigenetic modifiers in clear cell renal cell carcinoma.

Arseneault M, Monlong J, Vasudev NS, Laskar RS, Safisamghabadi M, Harnden P, Egevad L, Nourbehesht N, Panichnantakul P, Holcatova I, Brisuda A, Janout V, Kollarova H, Foretova L, Navratilova M, Mates D, Jinga V, Zaridze D, Mukeria A, Jandaghi P, Brennan P, Brazma A, Tost J, Scelo G, Banks RE, Lathrop M, Bourque G, Riazalhosseini Y.

Sci Rep. 2017 Mar 23;7:44876. doi: 10.1038/srep44876.

9.

Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice.

Jandaghi P, Najafabadi HS, Bauer AS, Papadakis AI, Fassan M, Hall A, Monast A, von Knebel Doeberitz M, Neoptolemos JP, Costello E, Greenhalf W, Scarpa A, Sipos B, Auld D, Lathrop M, Park M, Büchler MW, Strobel O, Hackert T, Giese NA, Zogopoulos G, Sangwan V, Huang S, Riazalhosseini Y, Hoheisel JD.

Gastroenterology. 2016 Dec;151(6):1218-1231. doi: 10.1053/j.gastro.2016.08.040. Epub 2016 Aug 28.

PMID:
27578530
10.

Precision medicine from the renal cancer genome.

Riazalhosseini Y, Lathrop M.

Nat Rev Nephrol. 2016 Nov;12(11):655-666. doi: 10.1038/nrneph.2016.133. Epub 2016 Oct 3. Review.

PMID:
27694978
11.

Rational design and engineering of a mutant variant of urate oxidase as a therapeutic enzyme: a molecular dynamics simulation approach.

Ahrari S, Dabbagh F, Ahrari S, Ghasemi Y, Mogharrab N, Riazalhosseini Y.

Curr Comput Aided Drug Des. 2016 Sep 5. [Epub ahead of print]

PMID:
27600879
12.

RNA-Seq as a Tool to Study the Tumor Microenvironment.

Panichnantakul P, Bourgey M, Montpetit A, Bourque G, Riazalhosseini Y.

Methods Mol Biol. 2016;1458:311-37. doi: 10.1007/978-1-4939-3801-8_22.

PMID:
27581031
13.

Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.

Morin RD, Assouline S, Alcaide M, Mohajeri A, Johnston RL, Chong L, Grewal J, Yu S, Fornika D, Bushell K, Nielsen TH, Petrogiannis-Haliotis T, Crump M, Tosikyan A, Grande BM, MacDonald D, Rousseau C, Bayat M, Sesques P, Froment R, Albuquerque M, Monczak Y, Oros KK, Greenwood C, Riazalhosseini Y, Arseneault M, Camlioglu E, Constantin A, Pan-Hammarstrom Q, Peng R, Mann KK, Johnson NA.

Clin Cancer Res. 2016 May 1;22(9):2290-300. doi: 10.1158/1078-0432.CCR-15-2123. Epub 2015 Dec 8.

14.

Changes in the expression profiles of claudins during gonocyte differentiation and in seminomas.

Manku G, Hueso A, Brimo F, Chan P, Gonzalez-Peramato P, Jabado N, Gayden T, Bourgey M, Riazalhosseini Y, Culty M.

Andrology. 2016 Jan;4(1):95-110. doi: 10.1111/andr.12122. Epub 2015 Nov 20.

15.

Double Heterozygosity of BRCA2 and STK11 in Familial Breast Cancer Detected by Exome Sequencing.

Ataei-Kachouei M, Nadaf J, Akbari MT, Atri M, Majewski J, Riazalhosseini Y, Garshasbi M.

Iran J Public Health. 2015 Oct;44(10):1348-52.

16.

TCF12 is mutated in anaplastic oligodendroglioma.

Labreche K, Simeonova I, Kamoun A, Gleize V, Chubb D, Letouzé E, Riazalhosseini Y, Dobbins SE, Elarouci N, Ducray F, de Reyniès A, Zelenika D, Wardell CP, Frampton M, Saulnier O, Pastinen T, Hallout S, Figarella-Branger D, Dehais C, Idbaih A, Mokhtari K, Delattre JY, Huillard E, Mark Lathrop G, Sanson M, Houlston RS; POLA Network.

Nat Commun. 2015 Jun 12;6:7207. doi: 10.1038/ncomms8207.

17.

GHSR hypermethylation: a promising pan-cancer marker.

Jandaghi P, Hoheisel JD, Riazalhosseini Y.

Cell Cycle. 2015;14(5):689-90. doi: 10.1080/15384101.2015.1006051. No abstract available.

18.

GHSR DNA hypermethylation is a common epigenetic alteration of high diagnostic value in a broad spectrum of cancers.

Moskalev EA, Jandaghi P, Fallah M, Manoochehri M, Botla SK, Kolychev OV, Nikitin EA, Bubnov VV, von Knebel Doeberitz M, Strobel O, Hackert T, Büchler MW, Giese N, Bauer A, Muley T, Warth A, Schirmacher P, Haller F, Hoheisel JD, Riazalhosseini Y.

Oncotarget. 2015 Feb 28;6(6):4418-27.

19.

Variation in genomic landscape of clear cell renal cell carcinoma across Europe.

Scelo G, Riazalhosseini Y, Greger L, Letourneau L, Gonzàlez-Porta M, Wozniak MB, Bourgey M, Harnden P, Egevad L, Jackson SM, Karimzadeh M, Arseneault M, Lepage P, How-Kit A, Daunay A, Renault V, Blanché H, Tubacher E, Sehmoun J, Viksna J, Celms E, Opmanis M, Zarins A, Vasudev NS, Seywright M, Abedi-Ardekani B, Carreira C, Selby PJ, Cartledge JJ, Byrnes G, Zavadil J, Su J, Holcatova I, Brisuda A, Zaridze D, Moukeria A, Foretova L, Navratilova M, Mates D, Jinga V, Artemov A, Nedoluzhko A, Mazur A, Rastorguev S, Boulygina E, Heath S, Gut M, Bihoreau MT, Lechner D, Foglio M, Gut IG, Skryabin K, Prokhortchouk E, Cambon-Thomsen A, Rung J, Bourque G, Brennan P, Tost J, Banks RE, Brazma A, Lathrop GM.

Nat Commun. 2014 Oct 29;5:5135. doi: 10.1038/ncomms6135.

PMID:
25351205
20.

The prognostic ease and difficulty of invasive breast carcinoma.

Tofigh A, Suderman M, Paquet ER, Livingstone J, Bertos N, Saleh SM, Zhao H, Souleimanova M, Cory S, Lesurf R, Shahalizadeh S, Garcia Lopez N, Riazalhosseini Y, Omeroglu A, Ursini-Siegel J, Park M, Dumeaux V, Hallett M.

Cell Rep. 2014 Oct 9;9(1):129-142. doi: 10.1016/j.celrep.2014.08.073. Epub 2014 Oct 2.

Supplemental Content

Loading ...
Support Center